Ifm_05-may | 2022

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.

Lenalidomide was the primary drug used for maintenance in this study. Key Findings: IFM_05-May 2022

Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI A significant number of patients (roughly 27%) had

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods. IFM_05-May 2022

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.